Approval · Notice of Compliance 2216 · 2004
RETAVASE: Notice of Compliance 2216
Issued May 6, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2216
- Date
- May 6, 2004
- Company
- Centocor Inc.Leiden, Netherlands
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Changes to manufacturing process
- Therapeutic class
- Thrombolytic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RETAVASE | Not yet assigned | — |
Medicinal ingredients
- RETEPLASE 10.4 UNIT per VIAL